Company profile
Opto - welcome to the future of neurological treatment
Developing technology that improves the lives of people suffering from neurological disorders
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNTYzMzIxNWFkaXF6a2N4
Published 13 Sep 2024 13:48
Company registered at Companies House
1 May 2025 to 30 Apr 2028
1 Mar 2024 to 31 May 2025
Opto is a UK-based medical device SME with a core project team of Dr Ben Woodington (CEO), Dr Elise Jenkins (Project Lead/CTO) and Jose Lepe (Product Lead). Electrical monitoring devices are crucial for managing neurological diseases such as brain cancer, epilepsy, and Parkinson's disease. These conditions affect around 105K people annually in the UK alon...
1 Mar 2024 to 31 Aug 2024
Neurotechnology refers to a broad range of devices which can directly record and/or modulate the activity of the nervous system. These devices can either be implanted into the brain or nervous system (invasive) or placed on the surface of the skin (non-invasive). Neurotechnologies have been used, and are in development for, many different purposes, both m...
